You are here
Regulated information
|
February 26, 2020
bioMérieux – 2019 Financial Results
|
|
October 22, 2019
bioMérieux –Third-Quarter 2019 Business Review
|
|
September 05, 2019
Avis de mise à disposition du rapport financier semestriel 2019
|
|
September 05, 2019
Interim financial report 2018
|
|
September 04, 2019
bioMérieux – First-Half 2019 Results
|
|
May 13, 2014
bioMérieux Rapport du Président 2013
|
|
April 22, 2013
Avis de mise à disposition du Rapport du Président du Conseil d'administration sur le contrôle interne
|
|
April 22, 2013
Report of the Chairman of the Board of Directors on Corporate Governance and Internal control report
|
|
April 30, 2010
Rapport sur le gouvernement d'entreprise et le contrôle interne 2009
|
|
November 01, 2009
Prospectus 2008
|
|
May 13, 2014
bioMérieux Honoraires des commissaires aux comptes 2013
|
|
April 15, 2013
Honoraires des Commissaires aux Comptes 2012
|
|
April 28, 2010
Honoraires des Commissaires aux Comptes 2009 et 2008
|
|
June 11, 2009
Prospectus 2008
|
|
April 06, 2020
March 2020 - Declaration about number of shares issued and number of voting rights
|
|
March 05, 2020
February 2020 - Declaration about number of shares issued and number of voting rights
|
|
February 12, 2020
January 2020 - Declaration about number of shares issued and number of voting rights
|
|
January 13, 2020
December 2019 - Declaration about number of shares issued and number of voting rights
|
|
December 06, 2019
November 2019 - Declaration about number of shares issued and number of voting rights
|
|
October 10, 2013
Communiqué de mise à disposition du Prospectus Emission Obligataire visé par l'AMF Octobre 2013
|
|
May 07, 2004
Document de Base
|
|
May 21, 2020
CE marking of bioMérieux serology tests for SARS-CoV-2 on VIDAS®
|
|
May 19, 2020
Information concerning 2019 dividend and the bioMérieux General Shareholders’ Meeting
|
|
May 06, 2020
bioMérieux serology tests for SARS-CoV-2 on VIDAS® undergo validation preceding imminent launch
|
|
May 04, 2020
BIOFIRE® Respiratory Panel 2.1 (RP2.1) with SARS-CoV-2 obtains FDA Emergency Use Authorization
|
|
April 16, 2020
First-Quarter 2020 Business Review
|
|
May 22, 2020
Notice of information related to preparatory documents for the Ordinary and Extraordinary Shareholders’ Meeting of June 30, 2020
|
|
January 13, 2020
Biannual report on bioMérieux's liquidity agreement as of Dec 31, 2019
|
|
November 22, 2019
Disclosure of trading in own shares on November 22, 2019
|
|
November 15, 2019
Disclosure of trading in own shares on November 15, 2019
|
|
July 08, 2019
Bilan semestriel du contrat de liquidité au 30 juin 2019
|
|
July 08, 2019
Biannual report on bioMérieux's liquidity agreement as of Jun 30, 2019
|
No regulated information available